| Chronic Obstructive Airway Disease
Dalisrep vs Perforomist
Side-by-side clinical, coverage, and cost comparison for chronic obstructive airway disease.Deep comparison between: Daliresp vs Perforomist with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsPerforomist has a higher rate of injection site reactions vs Daliresp based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Perforomist but not Daliresp, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Daliresp
Perforomist
At A Glance
Oral
Daily
PDE4 inhibitor
Nebulization
Twice daily
Long-acting beta2-agonist (LABA)
Indications
- Chronic Obstructive Airway Disease
- Chronic Obstructive Airway Disease
- Bronchitis, Chronic
- Pulmonary Emphysema
Dosing
Chronic Obstructive Airway Disease Maintenance dose: 500 mcg once daily, with or without food; an optional titration of 250 mcg once daily for the first 4 weeks may reduce discontinuation rates, but 250 mcg is not the effective therapeutic dose.
Chronic Obstructive Airway Disease, Bronchitis, Chronic, Pulmonary Emphysema 20 mcg (one unit-dose vial) administered twice daily (morning and evening) by nebulization via standard jet nebulizer connected to an air compressor; total daily dose greater than 40 mcg is not recommended.
Contraindications
- Moderate to severe liver impairment (Child-Pugh B or C)
- Use without an inhaled corticosteroid in patients with asthma
Adverse Reactions
Most common (>=2%) Diarrhea, weight decreased, nausea, headache, back pain, influenza, insomnia, dizziness, decreased appetite
Serious Diarrhea, atrial fibrillation, lung cancer, prostate cancer, acute pancreatitis, acute renal failure
Postmarketing Hypersensitivity reactions (angioedema, urticaria, rash), gynecomastia
Most common (>=2%) Diarrhea, nausea, nasopharyngitis, dry mouth, vomiting, dizziness, insomnia
Serious Angina, hypertension or hypotension, tachycardia, arrhythmias, hypokalemia, hyperglycemia, metabolic acidosis
Postmarketing Anaphylactic reactions, urticaria, angioedema, rash, bronchospasm
Pharmacology
Roflumilast and its active metabolite (roflumilast N-oxide) are selective inhibitors of phosphodiesterase 4 (PDE4); inhibition of PDE4 leads to accumulation of intracellular cyclic AMP in lung tissue, which is thought to underlie its therapeutic action in COPD.
Long-acting beta2-adrenergic receptor agonist (LABA) that acts locally in the lung as a bronchodilator; stimulates adenyl cyclase to increase cyclic AMP levels, causing relaxation of bronchial smooth muscle and inhibition of mast cell mediator release.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Daliresp
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (11/12)
Perforomist
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (10/12)
UnitedHealthcare
Daliresp
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (7/8)
Perforomist
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (5/8)
Humana
Daliresp
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (3/3)
Perforomist
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Daliresp.
No savings programs available for Perforomist.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
DalirespView full Daliresp profile
PerforomistView full Perforomist profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.